{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:42:03Z","timestamp":1789663323898,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Universit\u00e4tsklinikum Magdeburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Achondroplasia is the most common type of skeletal dysplasia, caused by a recurrent pathogenic variant in the fibroblast growth factor receptor 3 (\n                    <jats:italic>FGFR3)<\/jats:italic>\n                    . The management of achondroplasia is multifaceted, requiring the involvement of multiple specialties across the life course. There are significant unmet needs associated with achondroplasia and substantial differences in different countries with regard to delivery of care. To address these challenges the European Achondroplasia Forum (EAF), a network of senior clinicians and orthopaedic surgeons from Europe and the Middle East representative of the achondroplasia clinical community, came together with the overall aim of improving patient outcomes. The EAF developed a consensus on guiding principles of management of achondroplasia to provide a basis for developing optimal care in Europe. All members of the EAF were invited to submit suggestions for guiding principles of management, which were consolidated and then discussed during a meeting in December 2020. The group voted anonymously on the inclusion of each principle, with the requirement of a 75% majority at the first vote to pass the principle. A vote on the level of agreement was then held. A total of six guiding principles were developed, which cover management over the lifetime of a person with achondroplasia. The principles centre on the lifelong management of achondroplasia by an experienced multidisciplinary team to anticipate and manage complications, support independence, and improve quality of life. There is focus on timely referral to a physician experienced in the management of achondroplasia on suspicion of the condition, shared decision making, the goals of management, access to adaptive measures to enable those with achondroplasia to access their environment, and the importance of ongoing monitoring throughout adolescence and adulthood. All principles achieved the 75% majority required for acceptance at the first vote (range 91\u2013100%) and a high level of agreement (range 8.5\u20139.6). The guiding principles of management for achondroplasia provide all healthcare professionals, patient advocacy groups and policy makers involved in the management of achondroplasia with overarching considerations when developing health systems to support the management of achondroplasia.\n                  <\/jats:p>","DOI":"10.1186\/s13023-021-01971-6","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T09:02:53Z","timestamp":1627722173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The first European consensus on principles of management for achondroplasia"],"prefix":"10.1186","volume":"16","author":[{"given":"Valerie","family":"Cormier-Daire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moeenaldeen","family":"AlSayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfeg","family":"Ben-Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio Bernardo","family":"de Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Boero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein O.","family":"Fredwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Encarna","family":"Guillen-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert","family":"Mortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zagorka","family":"Peijin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5113-8657","authenticated-orcid":false,"given":"Klaus","family":"Mohnike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"key":"1971_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.a.40433","volume":"179","author":"A Coi","year":"2019","unstructured":"Coi A, Santoro M, Garne E, Pierini A, Addor M-C, Alessandri J-L, et al. Epidemiology of achondroplasia: a population-based study in Europe. Am J Med Genet Part A. 2019;179:1\u20138.","journal-title":"Am J Med Genet Part A"},{"key":"1971_CR2","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","volume":"182A","author":"PK Foreman","year":"2020","unstructured":"Foreman PK, van Kessel F, van Hoorn R, van den Bosch J, Shediac R, Landis S. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am J Med Genet. 2020;182A:2297\u2013316.","journal-title":"Am J Med Genet"},{"key":"1971_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2042018820904016","volume":"11","author":"P Marzin","year":"2020","unstructured":"Marzin P, Cormier-Daire V. New perspectives on the treatment of skeletal dysplasia. Ther Adv Endocrinol Metab. 2020;11:1\u201316.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"1971_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","volume":"246","author":"DM Ornitz","year":"2017","unstructured":"Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Dev Dyn. 2017;246:291\u2013309.","journal-title":"Dev Dyn"},{"key":"1971_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14:1\u201319.","journal-title":"Orphanet J Rare Dis"},{"key":"1971_CR6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/adc.2010.189092","volume":"97","author":"MJ Wright","year":"2012","unstructured":"Wright MJ, Irving MD. Clinical management of achondroplasia. Arch Dis Child. 2012;97:129\u201334.","journal-title":"Arch Dis Child"},{"key":"1971_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2147\/TACG.S51485","volume":"7","author":"PJ Ireland","year":"2014","unstructured":"Ireland PJ, Pacey V, Zankl A, Edwards P, Johnston LM, Savarirayan R. Optimal management of complications associated with achondroplasia. Appl Clin Genet. 2014;7:117\u201325.","journal-title":"Appl Clin Genet"},{"key":"1971_CR8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.ajog.2018.07.017","volume":"219","author":"R Savarirayan","year":"2018","unstructured":"Savarirayan R, Rossiter JP, Hoover-Fong JE, Irving M, Bompadre V, Goldberg MJ, et al. Best practice guidelines regarding prenatal evaluation and delivery of patients with skeletal dysplasia. Am J Obstet Gynecol. 2018;219:545\u201362.","journal-title":"Am J Obstet Gynecol"},{"key":"1971_CR9","doi-asserted-by":"publisher","first-page":"e20201010","DOI":"10.1542\/peds.2020-1010","volume":"145","author":"J Hoover-Fong","year":"2020","unstructured":"Hoover-Fong J, Scott CI, Jones ME, AAP Committee on Genetics. Health supervision for people with achondroplasia. Pediatrics. 2020;145:e20201010.","journal-title":"Pediatrics"},{"key":"1971_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1136\/annrheumdis-2014-206350","volume":"74","author":"D Van der Heijde","year":"2015","unstructured":"Van der Heijde D, Aletaha D, Carmona L, Edwards CJ, Kvien TK, Kouloumas M, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74:8\u201313.","journal-title":"Ann Rheum Dis"},{"key":"1971_CR11","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/ajmg.a.31919","volume":"143A","author":"J Wynn","year":"2007","unstructured":"Wynn J, King TM, Gambello MJ, Waller DK, Hecht JT. Mortality in achondroplasia study: a 42-year follow-up. Am J Med Genet. 2007;143A:2502\u201311.","journal-title":"Am J Med Genet"},{"key":"1971_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/apa.15760","author":"JM Legare","year":"2021","unstructured":"Legare JM, Smid CJ, Modaff P, Pauli RM. Achondroplasia is associated with increased occurrence of apparent life threatening events. Acta Paediatr. 2021. https:\/\/doi.org\/10.1111\/apa.15760.","journal-title":"Acta Paediatr"},{"key":"1971_CR13","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1002\/ajmg.a.35947","volume":"161A","author":"KJ Schulze","year":"2013","unstructured":"Schulze KJ, Alade YA, McGready J, Hoover-Fong JE. Body Mass Index (BMI): the case for condition-specific cut-offs for overweight and obesity in skeletal dysplasias. Am J Med Genet. 2013;161A:2110\u20132.","journal-title":"Am J Med Genet"},{"key":"1971_CR14","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s11136-016-1455-7","volume":"26","author":"N Dhiman","year":"2017","unstructured":"Dhiman N, Albaghdadi A, Zogg CK, Sharma M, Hoover-Fong JE, Ain MC, et al. Factors associated with health-related quality of life (HRQOL) in adults with short stature skeletal dysplasias. Qual Life Res. 2017;26:1337\u201348.","journal-title":"Qual Life Res"},{"key":"1971_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cge.13542","volume":"97","author":"SO Fredwall","year":"2020","unstructured":"Fredwall SO, Maanum G, Johansen H, Snekkevik H, Savarirayan R, Lidal IB. Current knowledge of medical complications in adults with achondroplasia: a scoping review. Clin Genet. 2020;97:179\u201397.","journal-title":"Clin Genet"},{"key":"1971_CR16","unstructured":"WHO. Continuity and coordination of care. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274628\/9789241514033-eng.pdf?ua=1. Accessed 12 Feb 2021."},{"key":"1971_CR17","unstructured":"WHO. Framework on integrated, people-centred health services. Report by the Secretariat. https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA69\/A69_39-en.pdf. Accessed 12 Feb 2021."},{"key":"1971_CR18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10897-018-0294-9","volume":"28","author":"J Baumbusch","year":"2019","unstructured":"Baumbusch J, Mayer S, Sloan-Yip I. Alone in a crowd? Parents of children with rare diseases\u2019 experiences of navigating the healthcare system. J Genet Couns. 2019;28:80\u201390.","journal-title":"J Genet Couns"},{"key":"1971_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.62018","author":"EA Yonko","year":"2020","unstructured":"Yonko EA, Emanuel JS, Carter EM, Raggio CL. Quality of life in adults with achondroplasia in the United States. Am J Med Genet. 2020. https:\/\/doi.org\/10.1002\/ajmg.a.62018.","journal-title":"Am J Med Genet"},{"key":"1971_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.berh.2007.12.008","volume":"22","author":"G Baujat","year":"2008","unstructured":"Baujat G, Legeai-Mallet L, Finidori G, Cormier-Daire V, Le Merrer M. Achondroplasia. Best Pract Res Clin Rheumatol. 2008;22:3\u201318.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"1971_CR21","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/archdischild-2020-319625","volume":"106","author":"MS Cheung","year":"2021","unstructured":"Cheung MS, Irving M, Cocca A, Santos R, Shaunak M, Dougherty H, et al. Achondroplasia foramen magnum score: screening for infants for stenosis. Arch Dis Child. 2021;106:180\u20134.","journal-title":"Arch Dis Child"},{"key":"1971_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.3171\/2018.9.PEDS18410","volume":"23","author":"JL Nadel","year":"2018","unstructured":"Nadel JL, Wilkinson DA, Garton HJL, Muraszko KM, Maher CO. Screening and surgery for foramen magnum stenosis in children with achondroplasia: a large, national database analysis. J Neurosurg Pediatr. 2018;23:374\u201380.","journal-title":"J Neurosurg Pediatr"},{"key":"1971_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/BPO.0000000000000862","volume":"38","author":"A Margalit","year":"2018","unstructured":"Margalit A, McKean G, Lawing C, Galey S, Ain MC. Walking out of the curve: thoracolubar kyphosis in achondroplasia. J Pedatr Orthop. 2018;38:491\u20137.","journal-title":"J Pedatr Orthop"},{"key":"1971_CR24","first-page":"726","volume":"17","author":"RM Pauli","year":"1997","unstructured":"Pauli RM, Breed A, Horton VK, Glinski LP, Reiser CA. Prevention of fixed, angular kyphosis in achondroplasia. J Pediatr Orthop. 1997;17:726\u201333.","journal-title":"J Pediatr Orthop"},{"key":"1971_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1542\/peds.2005-1440","volume":"116","author":"TL Trotter","year":"2005","unstructured":"Trotter TL, Hall JG, AAP Committee on Genetics. Health supervision for children with achondroplasia. Pediatrics. 2005;116:771\u201383.","journal-title":"Pediatrics"},{"key":"1971_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","volume":"370","author":"WA Horton","year":"2007","unstructured":"Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370:162\u201372.","journal-title":"Lancet"},{"key":"1971_CR27","unstructured":"Coulter A, Collins A. Making shared decision-making a reality. No decision about me without me. London: King\u2019s Fund. 2011. https:\/\/www.kingsfund.org.uk\/sites\/default\/files\/Making-shared-decision-making-a-reality-paper-Angela-Coulter-Alf-Collins-July-2011_0.pdf Accessed 12 Feb 2021."},{"key":"1971_CR28","unstructured":"NICE. Shared decision making collaborative. A consensus statement. https:\/\/www.nice.org.uk\/Media\/Default\/About\/what-we-do\/SDM-consensus-statement.pdf. Accessed 12 Feb 2021."},{"key":"1971_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1440-1754.2011.02255.x","volume":"48","author":"PJ Ireland","year":"2012","unstructured":"Ireland PJ, Johnson S, Donaghey S, Johnston L, Ware RS, Zankl A, et al. Medical management of children with achondroplasia: evaluation of an Australasian cohort aged 0\u20135 years. J Pediatr Child Health. 2012;48:443\u20139.","journal-title":"J Pediatr Child Health"},{"key":"1971_CR30","doi-asserted-by":"publisher","first-page":"e20163020","DOI":"10.1542\/peds.2016-3020","volume":"138","author":"GJ Cohen","year":"2016","unstructured":"Cohen GJ, Weitzman CC, Committee on Psychological Aspects of Child and Family Health. Helping children and families deal with divorce and separation. Pediatrics. 2016;138:e20163020.","journal-title":"Pediatrics"},{"key":"1971_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s13023-019-1247-6","volume":"14","author":"C Saint-Laurent","year":"2019","unstructured":"Saint-Laurent C, Garde-Etayo L, Gouze E. Obesity in achondroplasia patients: from evidence to medical monitoring. Orphanet J Rare Dis. 2019;14:253.","journal-title":"Orphanet J Rare Dis"},{"key":"1971_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13023-019-1171-9","volume":"14","author":"S Witt","year":"2019","unstructured":"Witt S, Kolb B, Mohnike K, Bullinger M, Quitmann J. Quality of life of children with achondroplasia and their parents\u2014a German cross-sectional study. Orphanet J Rare Dis. 2019;14:194.","journal-title":"Orphanet J Rare Dis"},{"key":"1971_CR33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1758-0854.2010.01046.x","volume":"3","author":"I Cortinovis","year":"2011","unstructured":"Cortinovis I, Luraschi E, Intini S, Sessa M, Delle FA. The daily experience of people with achondroplasia. Apply Psychol Health Well Being. 2011;3:207\u201327.","journal-title":"Apply Psychol Health Well Being"},{"key":"1971_CR34","first-page":"109","volume":"15","author":"S Witt","year":"2017","unstructured":"Witt S, Rohenkohl A, Bullinger M, Sommer R, Kahrs C, Klingebiel KH, et al. Understanding, assessing and improving health-related quality of life on young people with achondroplaisa\u2014a collaboration between a patient organisation and academic medicine. Pediatr Endocrinol Rev. 2017;15:109\u201318.","journal-title":"Pediatr Endocrinol Rev"},{"key":"1971_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ajmg.a.61903","volume":"185A","author":"KM Pfeiffer","year":"2021","unstructured":"Pfeiffer KM, Brod M, Smith A, Gianettoni J, Viuff D, Ota S, et al. Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia. Am J Med Genet. 2021;185A:33\u201345.","journal-title":"Am J Med Genet"},{"key":"1971_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13023-020-01397-6","volume":"15","author":"SO Fredwall","year":"2020","unstructured":"Fredwall SO, Steen U, de Vries O, Rustad CF, Eggesb\u00f8 HB, Weedon-Fekjaer H, et al. High prevalence of symptomatic spinal stenosis in Norwegian adults with achondroplasia: a population-based study. Orphanet J Rare Dis. 2020;15:123.","journal-title":"Orphanet J Rare Dis"},{"key":"1971_CR37","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1080\/09638288.2018.1447028","volume":"41","author":"J Blomemeke","year":"2019","unstructured":"Blomemeke J, Sommer R, Witt S, Dabs M, Badia FJ, Bullinger M, et al. Piloting and psychometric properties of a patient-reported outcome instrument for young people with achondroplasia based on the International Classification of Functioning Disability and Health: the Achondroplasia Personal Life Experience Scale (APLES). Disabil Rehabil. 2019;41:1815\u201325.","journal-title":"Disabil Rehabil"},{"key":"1971_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/cge.12045","volume":"84","author":"Y Alade","year":"2013","unstructured":"Alade Y, Tunkel D, Schulze K, McGready J, Jallo G, Ain M, et al. Cross-sectional assessment of pain and physical function in skeletal dysplasia patients. Clin Genet. 2013;84:237\u201343.","journal-title":"Clin Genet"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01971-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01971-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01971-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T21:04:33Z","timestamp":1627765473000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01971-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01971-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,31]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB, TB-O, CL and ZP have no conflict of interest to declare. MDS has received honoraria or consultation fees from BioMarin, Sanofi Genzyme and Takeda. SBS has received grants or research support from Therachon\/Pfizer and Ascendis and honoraria or consultation fees from BioMarin and Ascendis. VC-D has received honoraria or consultation fees from BioMarin. SF has received consultation fees from BioMarin. EG-N has received grants or research support from BioMarin and Alnylam (paid to her institution) and honoraria or consultation fees from BioMarin, Alnylam, UCB and Takeda. MI has received honoraria or consultation fees from BioMarin, Therachon\/Pfizer, Sanofi, QED Therapeutics, Ascendis, Alexion, Kyowa Kirin. MM has received grants or research support from Pfizer and Merck, and honoraria or consultation fees from Pfizer, Merck, Novo Nordisk, Ferring, Ascendis, Sandoz and BioMarin. KM has received honoraria or consultation fees from BioMarin, Kyowa Kirin and QED. GM has received honoraria or consultation fees from BioMarin and Pfizer.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"333"}}